CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Operating activities:
Net income	$ 203,910	$ 68,373
Adjustments to reconcile net income to net cash provided from operating activities:
Loss (gain) from equity method investments, net of distributions	3,096	(1,552)
Deferred income tax expense	136,928	50,314
Depletion, depreciation and amortization and impairment	287,034	235,837
Exploration dry hole costs	1	(159)
Abandonment and impairment of unproved properties	19,327	34,374
Derivative fair value loss (income)	170,959	(37,885)
Cash settlements on derivative financial instruments that do not qualify for hedge accounting	(130,762)	(21,384)
Allowance for bad debt	250	250
Amortization of deferred financing costs, loss on extinguishment of debt and other	29,812	16,662
Deferred and stock-based compensation	47,912	63,325
Gain on the sale of assets	(281,711)	(83,121)
Changes in working capital:
Accounts receivable	1,275	(2,143)
Inventory and other	(6,872)	1,545
Accounts payable	20,115	(10,381)
Accrued liabilities and other	(59,751)	(34,166)
Net cash provided from operating activities	441,523	279,889
Investing activities:
Additions to natural gas and oil properties	(546,354)	(592,692)
Additions to field service assets	(5,119)	(2,033)
Acreage purchases	(110,471)	(27,449)
Equity method investments	1,103	1,885
Proceeds from disposal of assets	146,140	296,068
Purchases of marketable securities held by the deferred compensation plan	(11,251)	(20,213)
Proceeds from the sales of marketable securities held by the deferred compensation plan	13,343	16,342
Net cash used in investing activities	(512,609)	(328,092)
Financing activities:
Borrowing on credit facilities	1,175,000	893,000
Repayment on credit facilities	(1,195,000)	(1,323,000)
Issuance of subordinated notes		750,000
Repayment of subordinated notes	(312,000)	(259,063)
Dividends paid	(13,114)	(13,057)
Debt issuance costs		(12,324)
Issuance of common stock, net of offering expenses	396,662	343
Change in cash overdrafts	4,679	(1,155)
Proceeds from the sales of common stock held by the deferred compensation plan	14,803	13,491
Net cash provided from financing activities	71,030	48,235
(Decrease) increase in cash and cash equivalents	(56)	32
Cash and cash equivalents at beginning of period	348	252
Cash and cash equivalents at end of period	$ 292	$ 284